Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5N8 antigen + AS03A
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
H5N8 antigen + AS03A is an investigational, inactivated monovalent influenza vaccine candidate composed of the hemagglutinin (HA) antigen from the avian influenza A/H5N8 virus formulated with the adjuvant system AS03A. The vaccine is designed to induce protective immune responses against H5N8 and potentially other related H5 clade viruses. The AS03A adjuvant is an oil-in-water emulsion containing squalene, DL-α-tocopherol (vitamin E), and polysorbate 80, which enhances both humoral and cellular immune responses while enabling dose sparing of the viral antigen[1][2][5]. This combination aims to provide robust immunogenicity, including cross-clade antibody responses, making it a potential tool for pandemic preparedness against zoonotic avian influenza strains such as H5N8[2][5]. Clinical studies are ongoing to evaluate its safety and immunogenicity in adults[5].
- Brand names
- FLU Q-PAN H5N8 + AS03 adjuvant
- Other names
- Q-Pan H5N8Monovalent influenza H5N8 vaccineInfluenza A/Astrakhan/3212/2020-like (H5N8) virus vaccine
02
Targets
H5 HA (Influenza A hemagglutinin H5)
Beyond the preview
Go deeper on H5N8 antigen + AS03A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5N8 antigen + AS03A.